IDS - 12/21/2006

Attorney's Docket No.: 14875-148US1 / C1-A0231P-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tetsuo Kojima Art Unit: 1643

Serial No.: 10/542,839 Examiner: Lynn Anne Bristol

Filed : December 13, 2005 Conf. No. : 8994

Title : METHODS OF SCREENING FOR ANTIBODY LIGHT CHAINS

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant requests consideration of the references listed on the attached PTO-1449 form.

An English translation of foreign language reference AC is not included, since it is a member of the patent family of English language reference AB.

Applicant wishes to bring to the Examiner's attention co-pending and co-owned non-provisional application serial numbers 10/510,971 (Attorney Docket No. 14875-134US1) and 10/560,098 (Attorney Docket No. 14875-154US1), which concern related subject matter, and some of which have overlapping inventorship with the above-referenced application. Applicant assumes that the Examiner has ongoing access to the files of these related applications and can obtain copies of prosecution documents from the files if at any point in the future she considers it potentially relevant to issues in the present application. Applicant will supply copies of such documents from the related applications' files, should the Examiner request them.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:December 21, 2006

/Janis K. Fraser/

Janis K. Fraser, Ph.D., J.D.

Reg. No. 34,819

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110 Telephone: (617) 542-5070

Facsimile: (617) 542-8906

21518638.doc

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-148US1	Application No. 10/542,839
	closure Statement pplicant	Applicant Tetsuo Kojima	
	heets if necessary)	Filing Date	Group Art Unit
(37 CFR 81 98(b))		December 13, 2005	1643

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

	Foreig	n Patent Doc	uments or F	ublished Foreign	Patent /	Application	ns	
Examiner Initial	Desig.	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Transl Yes	ation No
LAB	AB	CA 2 331 641	11/11/1999	Canada	·	Capolaco	103	
\	AC	DE 198 19 846	11/11/1999	Germany			see AB	
	AD	WO 96/34892	11/07/1996	WIPO				
	, AE	WO 00/44788	08/03/2000	WIPO				
	AF	WO 01/44282	06/21/2001	WIPO				
	AG	WO 01/70775	09/27/2001	WIPO				

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Desig.		Decument
Initial ID		Document
LAB AH		De Jonge et al., "Production and Characterization of Bispecific Single-Chain Antibody Fragments," Mol. Immunol., 32:1405-1412 (1995)
	AI	Hudson et al., "High avidity scFv multimers; diabodies and triabodies," J. Immunol. Methods, 231:177-189 (1999)
	AJ	Kipriyanov et al., "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies," J. Mol. Biol., 330:99-111 (2003)
	AK	Krebber et al., "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system," <i>J. Immunol. Methods</i> , 201:35-55 (1997)
	AL	Kurucz et al., "Retargeting of CTL by an Efficiently Refolded Bispecific Single-Chain Fv Dimer Produced in Bacteria," J. Immunol., 154:4576-4582 (1995)
	AM	Little et al., "Of mice and men: hybridoma and recombinant antibodies," <i>Immunol. Today</i> , 21:364-370 (2000)
	AN	Peipp et al., "Bispecific antibodies targeting cancer cells," Biochem. Soc. Trans., 30:507-511 (2002)
	AO	Plückthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments," <i>Immunotechnology</i> , 3:83-105 (1997)
	AP	Ridgway et al., "'Knobs-into-holes' engineering of antibody C _H 3 domains for heavy chain heterodimerization," <i>Protein Eng.</i> , 9:617-621 (1996)
	· AQ	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the <i>HER2</i> Protooncogene," <i>J. Exp. Med.</i> , 175:217-225 (1992)
\ \rac{1}{2}	AR	Skerra, "Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in <i>Escherichia coli</i> ," <i>Gene</i> , 151:131-135 (1994)

Examiner Signature /Lynn Br	istol/	Date Considered	02/08/2007
EXAMINER: Initials citation considered, Di	aw line through citation if no	ot in conformance and	not considered. Include copy of this form with

Communication to applicant.

Substitute Disclosure Form (PTO-1449)

next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-148US1	Application No. 10/542,839	
	losure Statement plicant	Applicant Tetsuo Kojima		
(Use several she (37 CFR §1.98(b))	eets if necessary)	Filing Date December 13, 2005	Group Art Unit 1643	

(Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document			
488	AS	Völkel et al., "Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies," <i>Protein Eng.</i> , 14:815-823 (2001)			
J	AT	Zuo et al., "An efficient route to the production of an IgG-like bispecific antibody," <i>Protein Eng.</i> , 13:361-367 (2000)			

Examiner Signature	/Lynn Bristol/	Date Considered 02/08/2007
EVALUATED: Initials site	tion considered. Draw line through citation if n	at in conformance and not considered. Include conv of this form with

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	1	of	1

	•		\
1 of 1		`	
1 of 1			//

Substitute Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-148US1	Application No. 10/542,839	
Info ation Disc	closure Statement oplicant	Applicant Tetsuo Kojima	
APR I 4 2006 (LES) several sh	neets if necessary)	Filing Date December 13, 2005	Group Art Unit
PACE			

			U.S. Paten	t Documents			· ·
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						·
	AC						
	AD			. •			
	AE		,				
	AF						
	AG						
	AH						
	AI						

Examiner Initial		Desig. ID AJ	Document Number WO 98/50431	Publication Date 11/12/1998	Country or Patent Office WIPO	Class	Subclass	Translation	
								Yes	. No
		AK	WO 03/087163	10/23/2003	WIPO			х	
		AL	JP 2001-523971	11/27/2001	Japan			,	х
	·	AM	EP 0774511	5/21/1997	Europe				
	,	AN							
		AO					·		ļ —

Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
LAB	AP	Carter, "Bispecific human IgG by design," J. Immunol. Methods, 248:7-15 (2001)					
	AQ	Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," Nucleic Acids Res., 19:4133-7 (1991)					
	AR	Merchant et al., "An efficient route to human bispecific IgG," Nat. Biotechnol., 16:677-81 (1998)					
	AS						
	AT	·					

Examiner Signature	Date Considered
/Lynn Bristol/	02/08/2007
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t In conformance and not considered. Include copy of this form with

Substitute Disclosure Form (PTO-1449)